Ltd., a leading Japanese pharmaceutical company with extensive experience in marketing rare disease therapeutics in the U.S. Under the terms of the agreement, Nippon Shinyaku received an option to ...
"Monogenic IL-18 driven hyperinflammation is a rare, serious, and potentially life-threatening condition without any ... This is a novel and promising approach for the treatment of several autoimmune ...